4.3 Article

Evaluation of a novel blood microsampling device for clinical trial sample collection and protein biomarker analysis

期刊

BIOANALYSIS
卷 12, 期 13, 页码 919-935

出版社

Newlands Press Ltd
DOI: 10.4155/bio-2020-0063

关键词

biomarkers; COVID-19; DBS; microsampling; patient-centric sampling; proteomics; sampling device; SomaScan; TAP; VAMS

资金

  1. Novartis

向作者/读者索取更多资源

Aim: Evaluation of a novel microsampling device for its use in clinical sample collection and biomarker analysis. Methodology: Matching samples were collected from 16 healthy donors (ten females, six males; age 42 +/- 20) via K2EDTA touch activated phlebotomy (TAP) device and phlebotomy. The protein profile differences between sampling groups was evaluated using aptamer-based proteomic assay SomaScan and selected ELISA. Conclusion: Somascan signal concordance between phlebotomy- and TAP-generated samples was studied and comparability of protein abundances between these blood sample collection methods was demonstrated. Statistically significant correlation in selected ELISA assays also confirmed the TAP device applicability to the quantitative analysis of protein biomarkers in clinical trials.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据